Meeting
2014 ASCO Annual Meeting
Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover.
Authors
Gareth J Morgan
Centre for Myeloma Research, Institute of Cancer Research, London, United Kingdom
Gareth J Morgan , Jesus San Miguel , Sujith Dhanasiri , Dawn Lee , Antonio Palumbo , Thierry Facon , Mohamed H. Zaki , Xin Yu , Lars Axel Sternas , Christian Jacques , Katja C. Weisel , Fritz Offner , Meletios A. Dimopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01311687
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8593)
DOI
10.1200/jco.2014.32.15_suppl.8593
Abstract #
8593
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial.
First Author: Katja Weisel
Poster
2013 ASCO Annual Meeting
Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.
First Author: Kevin W. Song
Poster
2016 ASCO Annual Meeting
Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.
First Author: Philippe Moreau
Poster
2015 ASCO Annual Meeting
![MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).](https://d201v5jt9ylckg.cloudfront.net/156/9331/115230/115230_poster_pv.jpg)
MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
First Author: Paul G. Richardson